Webinar: Accessing CAR T-cell Therapy from a Regional, Rural and Remote Perspective

When

Date: Tuesday 8 July
Time: 4:00pm – 5:30pm AEST

Time zone conversions:

QLD/NSW/VIC/ACT/TAS: 4:00pm – 5:30pm (AEST)
SA/NT: 3:30pm – 5:00pm
WA: 2:00pm – 3:30pm

Event Details

Join us for an important webinar focused on the availability and accessibility of CAR T-cell therapy for people living with lymphoma in rural, regional and remote communities, sponsored by Gilead. This session will include real-world case studies highlighting current challenges and solutions in care delivery, followed by a live Q&A.

Speakers

Dr Allison Barraclough – Lymphoma Lead and CAR-T Program Director at Fiona Stanley Hospital, Perth WA. Dr Barraclough has a special interest in immunological treatments for lymphoma and in supporting patients in rural and remote areas living with haematological malignancies.

Dr Safia Belbachir – Haematology Fellow specialising in BMT and CAR-T cell therapy, currently working as a Clinical Trials Fellow at Fiona Stanley Hospital WA.

This is a valuable opportunity for patients, carers and healthcare professionals to gain insight into treatment options and innovations available beyond metropolitan centres.

Registration is free.

There is limited availability for this event, so secure your spot quickly.

This event has already taken place.

Details

Date: Tuesday 8th of July 2025

Time: 4:00pm AEST - 5:30pm AEST

Support and information

Patient Online Forum

Find Out More

Order Our Resources

Find Out More

Fundraise for us

Get started

Sign up to our Newsletter

Lymphoma Australia is the only incorporated charity in Australia dedicated to solely providing education, support, awareness and advocacy initiatives for Australians touched by lymphoma and chronic lymphocytic leukemia (CLL).

Contact Lymphoma Australia Today!

Patient Support Hotline

General Enquiries

Please note: Lymphoma Australia staff are only able to reply to emails sent in English language.

For people living in Australia, we can offer a phone translation service. Have your nurse or English speaking relative call us to arrange this.

Useful Definitions

Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
Relapsed: This means the lymphoma came back after being gone for a while after treatment.
2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here.

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.